Katherine Stephenson's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (3)
IntroductionThe DolastatinsDiscovery and Preclinical Pharmacokinetics of TasidotinPreclinical Pharmacology of Tasidotin and ILX651-C-CarboxylateToxicology of TasidotinClinical Pharmacology and Studies of Tasidotin in Patients with Solid TumorsClinical Pharmacology of ILX651-C-CarboxylateExposure–Response RelationshipsDiscussionSummaryReferences
The treatment of acute leukaemias, which are the most common paediatric cancers, has improved considerably in recent decades, with complete response rates approaching approximately 90% in some cases. However, there remains a major need for treatments for patients who do not achieve or maintain complete remission, for whom the prognosis is very poor...
Citations
... Tasidotin has also been shown to have unique effects on microtubules (3). At low concentrations (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40) Amol/L), tasidotin seems to induce a prolonged lag phase in microtubule assembly, which is followed by the standard rate of microtubule assembly. At higher concentrations (>50 Amol/L), tasidotin inhibits the extent of microtubule assembly and induces a long lag time, which is not a feature of other antimicrotubule agents. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/301091108474882-1448797122184_Q64/Maria-Kavallaris.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/278709467664392-1443460923782_Q64/Richard-Luduena.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/550906900619264-1508357848898_Q64/Steve-Weitman.jpg)
... In industry, NPs are attractive biocatalysts for the synthesis of nucleoside analogs which are widely used for the treatment of viral infections and cancer (Bonate et al., 2006;De Clercq & Li, 2016;Flexner, 2007). Chemo-enzymatic production of nucleoside analogs has many advantages compared to chemical synthesis, which is still the "golden standard" in industrial production. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272748777832449-1442039784029_Q64/Peter-Bonate.jpg)
